FDA User Fees: Highlights from FDARA & Our Forecast for the Next Round | Mintz
Description
As discussed in an earlier blog post, the process for reauthorizing human medical product user fee programs at the Food and Drug Administration (FDA) for another 5-year period is getting started this year. Below we highlight some changes made to the programs when they were last reauthorized through